Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CART-EGFR-IL13Rα2 Cells in Newly Diagnosed Glioblastoma
NCT06973096Phase 1Active, not recruiting
- Sponsor
- University of Pennsylvania
- Start
- Jul 2025
- Primary completion
- Jul 2042
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of bivalent CAR-T (anti-EGFR) in glioblastoma (GBM) (2 cohorts), sponsored by University of Pennsylvania. Primary endpoints: Treatment-related adverse events at 15 years and Treatment-limiting toxicities at 28 days. Started Jul 2025; status: active, not recruiting.
02
Drugs
bivalent CAR-T (anti-EGFR)
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT06973096.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06973096.